KEY COMPOUND PATENT FOR PLEDOX® AND ALADOTE® SET TO GAIN US APPROVAL
September 22, 2015
PledPharma AB Company Announcement KEY COMPOUND PATENT FOR PLEDOX® AND ALADOTE® SET TO GAIN US APPROVAL PledPharma AB (publ) today reports that the United States Patent and Trademark Office (USPTO) has announced a "Notice of Allowance" for PledPharma's patent for the active ingredient of the drug candidates PledOx® and Aladote®. A Notice of Allowance means that the USPTO intends to grant the application. Stockholm, 2015-09-22 08:30 CEST (GLOBE NEWSWIRE) -- The announcement from the USPTO refers to patent application 14/369, 153, entitled "Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment". The patent term extends to December 2032 "The compound patent for PledOx® and Aladote® offers strong intellectual property protection in the US market and is therefore of great value to us, not least in negotiations with potential licensees for our most advanced project PledOx®. The patent for which we received a Notice of Allowance is the centerpiece of our broad patent portfolio, "said PledPharma CEO Jacques Näsström. PledOx® has been developed to provide patients with colorectal cancer protection against the chemotherapy induced nerve damage that often occurs in conjunction with cancer treatment. These kind of side effects often lead to the prescribed chemotherapy dose having to be reduced, or, in the worst case, to discontinuation of the treatment. Aladote® is a drug candidate with the potential to prevent the acute liver failure associated with overdoses of acetaminophen - the most common method of suicide attempts among young people aged 10-19 years. FOR FURTHER INFORMATION CONTACT: Jacques Näsström, CEO PledPharma AB cell: +46 73 713 09 79 e-mail: [email protected] PLEDPHARMA IN BRIEF PledPharma develops new drugs that protect the body against oxidative stress – a condition that can be caused by chemotherapy treatment and acetaminophen (paracetamol) poisoning. The company's most advanced project PledOx® reduces the nerve damage associated with chemotherapy. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. The project PP-099 seeks to limit the damage that occurs to the heart muscle during myocardial infarction. PledPharma’s most advanced project with PledOx® has completed Phase II trial. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bankaktiebolag is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se PledPharma AB discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act
